Trending

Newsletter

Abortion Pill Is Snake Oil for Canadian Women, Taxpayers

By: Johanne Brownrigg - @johanbrownrigg - Jan 27, 2015, 7:12 am

Español Health Canada have delayed their decision on the application for RU 486, the “abortion pill,” and drawn the ire of the drug’s proponents. Close scrutiny of this abortifacient’s side effects, however, makes the delay understandable, and why it hasn’t been rejected outright is the mystery.

RU-486 is a two-drug combo offered at five to nine weeks gestation: mifepristone blocks progesterone, and misoprostol, taken two days later, brings on contractions. According to the manufacturer, use of this drug requires an ultrasound before taking the first pill and again after the dead baby has been delivered, but the abortion takes place in the comfort of one’s own home.

Since doing anything in the comfort of one’s own home should be a medical benchmark, Health Canada’s critics are accusing their system of being inferior to many other countries where this drug is available. I take it as a test of our health care’s superiority.

Former abortionist Carol Everett has spoken candidly about Planned Parenthood’s use and abuse of this drug. In a Christian Week interview, she told Craig McCartney that “They use it as a way to double-dip on abortions. They know it only works in the first 49 days, but they use it up to 63 days.… They can get two procedures out of one woman. It’s a deliberate thing.”

Planned Parenthood, she explained, has each girl sign an agreement to have a surgical abortion if the RU-486 fails to complete the abortion. The woman is then charged again for the procedure. This occurs in a country where the patient pays. What will it mean in a taxpayer-funded system?

In 2007, Norine Dworkin-McDaniel took RU-486, and she subsequently titled her story in Marie Claire, “Betrayed by a Pill.” The description of her suffering is a warning to all women, but I would go further. Women have been betrayed by a movement, a movement that would also betray the Canadian health-care system. It isn’t a trite point.

Young people from Canada traveled to Washington, DC, and the 2015 March for Life, to challenge that abortion benefits women and seek "full legal protection from the moment of conception." (Campaign Life Coalition)
Young people from Canada traveled to Washington, DC, and the 2015 March for Life, to challenge the notion that abortion benefits women and seek “full legal protection from the moment of conception.” (Campaign Life Coalition)

In Canada, our generous health-care system is being stretched by the demands of an aging population, the expectations of a pampered populace, and the incredible medical breakthroughs that have developed wonder drugs and treatments — expensive wonder drugs and treatments. RU-486 would likely fall under the abortion umbrella and be fully funded by provincial health care, and at a time when Canadians are having other pharmaceutical and medical treatment options limited.

Provincial health-care ministers are weighing funding for the necessary against the next fabulous discovery that could change everything. These are important conversations to have. Deciding how to balance competing needs and how to achieve the greater good, matters. The taxpayer matters.

The taxpayer is also a patient. RU-486 betrays an unborn child. It betrays a vulnerable woman. It betrays a health-care system of its resources. No matter how we choose to examine the effect of this drug, no one comes out a winner.

Johanne Brownrigg Johanne Brownrigg

Johanne Brownrigg is the lobbyist for the Campaign Life Coalition. Based in Ottawa, Ontario, she blogs for ProWomanProLife and has been published in MercatorNet. Follow @johanbrownrigg.